EUCTR2014-000174-19-DE进行中（未招募）1 期
Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A Prospective Randomized Multicenter Study comparing Thrombopoetin-Receptor agonist Eltrombopagwith Placebo in Patients with Acquired Moderate Aplastic Anemia who are treated with Ciclosporin A - EMAA
niversitätsklinikum Ulm0 个研究点目标入组 90 人开始时间: 2014年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Current diagnosis of a Moderate Aplastic Anemia requiring standard treatment with CSA without prior specific therapy.
- •MAA is defined as Aplastic Anemia fulfilling the following criteria:
- •no evidence for other disease, causing marrow failure
- •hypocellular bone marrow for age
- •depression of at least two out of three peripheral blood counts below the normal values in two different blood samples in a time span from at least two weeks:
- •absolute neutrophil count (ANC) < 1.2 G/L
- •platelet count < 70 G/L
- •absolute reticulocyte count < 60 G/L21
- •without fulfilling the criteria for SAA (hypocellularity of bone marrow 25 % and depression of two of the three peripheral counts: ANC < 0.5 G/L, platelet count < 20 G/L, reticulocyte count < 20 G/L)
- •2. In this study need for treatment with CSA is defined as:
- •a. transfusion-independent MAA and:
- •ANC < 1.0 G/L
- •or hemoglobin < 8.5 g/dl and reticulocyte count < 60 G/L
- •or platelet count < 30 G/L
- •or significant clinical symptoms (infections, bleeding, anemia)
- •b. transfusion-dependent MAA:
- •Platelet transfusion dependency is defined as prophylactic transfusion (platelet counts < 10 G/L with no bleeding) or therapeutic transfusion in the 12 weeks prior to study entry.
- •Red blood cell transfusion dependency is defined as transfusion of at least 4 units of packed red blood cell
- •concentrates (PRBC) in the 12 weeks prior to study entry.
- •3. A signed and dated informed consent is necessary before the conduct of any study-specific procedure.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 90
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 90
排除标准
- •1. Age < 18 years
- •2. Constitutional Aplastic Anemia (i.e. Fanconi anemia or Dyskeratosis congenita)
- •3. Clonal myeloid disorders based on cytogenetic findings performed within 12 weeks of study entry. Especially patients with cytogenetic abnormalities which are recurrent in MDS are not eligible for the
- •4. Bone marrow reticulin fibrosis of grade 3 or greater
- •5. Severe concurrent diseases precluding the patient's ability to tolerate protocol therapy
- •6. ALT > 3 times the upper limit of normal if this elevation is progressive, or persistent during the 4 weeks before study entry or accompanied by increased direct bilirubin, or accompanied by clinical symptoms of liver injury or evidence for hepatic decompensation
- •7. Infection not adequately responding to appropriate therapy
- •8. HIV-positivity (patients with Hepatitis B or Hepatitis C are only in combination with hepatic failure - see
- •criteria 7- excluded)
- •9. Moribund status with a likely death within 3 months.
- •10. History of malignancy other than localized tumors diagnosed more than one year previously and treated surgically with curative intent (for instance squamous cell or other skin cancers, stage 1, breast cancer in
- •situ, cervical carcinoma in situ...).
- •11. Prior specific treatment of Aplastic Anemia with immuno-suppression or androgens or interleukin2- receptor-antibodies. The use of these drugs in context with other disorders before diagnosis of aplastic anemia is not an exclusion criteria if these treatments were finished longer than 6 months before study entry.
- •12. Treatment with other hematological effective drugs (including erythropoetin) within 3 months before study
- •entry as well as treatment with corticosteroids and GCSF within 3 weeks before enrollment.
- •13. Known hypersensitivity to Eltrombopag or its components
- •14. Known hypersensitivity to Ciclosporin.
- •15. Current nursing, pregnancy, or unwillingness to take oral contraceptives or use a barrier method of birth
- •control to refrain from pregnancy as well as a missing or positive pregnancy test within the last 14 days before inclusion for women of childbearing potential during the course of this study.
- •16. Inability to understand the investigational nature of the study or to give informed consent.
- •17. Renal failure with creatinine > 2× upper limit of normal.
- •18. Uncontrolled hypertension.
- •19. Participation in any study using an investigational drug or treatment with an investigational drug within 30 days preceding the first dose of study medication.
研究者
相似试验
已完成
2 期
Efficacy and Safety of Eltrombopag to correct thrombocytopenia in moderate to severe dengue patients- a Phase II Randomized Controlled Clinical TrialDengue Fever (DF), Dengue Haemorregic Fever (DHF) and Dengue Shock Syndrome (DSS)SLCTR/2019/037Incepta Pharmaceuticals Ltd.100
已完成
不适用
Evaluation of the efficacy and safety of thromboprophylaxis regimens in patients after the Fontan procedurePatients after the Fontan procedureJPRN-UMIN000044127Showa University1,903
撤回
不适用
Antithrombotic Treatment in patients with Effectively Maintained Sinus rhythm after Atrial Fibrillation ablatioKCT0000535Koera University Guro Hospital750
已完成
不适用
Clinical outcomes of endovascular embolization for the treatment of Spinal ArterioVenous Malformations (AVMs)IRCT2014071218457N1Vice chancellor for research, Imam Khomeini Hospital, Tehran University of Medical Sciences (TUMS)36
已完成
3 期
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.Idiopathic Thrombocytopenic PurpuraNCT01520909GlaxoSmithKline92